Abstract 1485P
Background
Pembrolizumab is the standard first-line treatment for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression of ≥50%. However, early loss of clinical benefit is observed in many cases. There is a need to identify predictors of this phenomenon in the real-world population.
Methods
This study is a retrospective analysis of patients (pts) with stage IV NSCLC treated with pembrolizumab in routine practice, who received treatment for at least 6 weeks. Inclusion criteria included good performance status (ECOG 0-1), no active brain metastases, and no EGFR or ALK alterations. The median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test and Cox regression model were used for uni- and multivariate analysis.
Results
A group of 216 pts were included. The objective response rate was 35.6%, 25.5% of pts had PD, while 11.2% of pts died before the first CT-scan. Median PFS and OS were 9.88 months (95% CI 4.85-14.92; 127 events) and 14.88 months (95% CI 9.84-19.91; 122 events), respectively. The median Systemic Inflammatory Index (SII) was 1260 in the overall population. In univariate analysis, SII >1260 had a negative impact on PFS (p=0.047) and OS (p<0.022). Tumour burden ≥111.5 mm (p<0.045) was a negative prognostic factor for OS. Other factors assessed were not relevant. An increase in the SII of more than 25% after 6 weeks of treatment correlated with a higher likelihood of early progression (p<0.001) and shorter OS (p<0.001). The differences were more pronounced in the subgroup of patients with an initial SII >1260. On multivariate analysis, higher tumour burden (HR 1.52, p=0.028, 95%CI 1.043-2.018) and an increase in SII at 6 weeks of more than 25% (HR 2.62, p<0.001;95%CI 1.625-4.234) were found to be negative prognostic factors for OS.
Conclusions
Pembrolizumab is effective in pts treated in daily practice. Taking into account additional factors, such as inflammatory index, may help to identify the optimal patient population. The dynamics of SII after 6 weeks of treatment may be a surrogate for clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Knetki-Wroblewska: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, MSD, Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen; Financial Interests, Personal, Advisory Board: Takeda, Boehringer Ingelheim, Bristol Myers Squibb. A. Piórek: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Takeda. S. Tabor: Financial Interests, Personal, Invited Speaker: MSD, BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Travel grant: AstraZeneca. K. Winiarczyk: Financial Interests, Personal, Invited Speaker: BMS, Pfizer. P. Sobczuk: Financial Interests, Personal, Other, Travel grant: Novartis; Financial Interests, Personal, Other, Travel Grant: MSD, BMS; Financial Interests, Personal, Invited Speaker: Swixx BioPharma, BMS, Gilead; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Stocks/Shares: CelonPharma; Non-Financial Interests, Institutional, Product Samples: Immutep; Non-Financial Interests, Leadership Role, Board Member, Chair of Young Oncologists Section: Polish Society of Clinical Oncology. A. Pluzanski: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal, Advisory Board: MSD, BMS. D.M. Kowalski: Financial Interests, Personal, Advisory Board: MSD, BMS; Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal and Institutional, Coordinating PI: MSD. M.J. Krzakowski: Financial Interests, Personal, Other, travel grant: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Other, Travel grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21